You’re Busted: Mylan Bilks Medicaid, Feds Confirm

by Admin | October 6, 2016 1:51 pm

October 6, 2016—EpiPen manufacturer Mylan cheated Medicaid out of millions of dollars of drug rebates for almost 20 years by misclassifying the product as a generic, two senior members of Congress said yesterday after the Centers for Medicare & Medicaid Services confirmed the situation in a letter.

Although CMS didn’t address the matter in the letter, others in Congress want to know if Mylan simultaneously bilked safety-net hospitals and health centers out of 340B drug discounts[1] on EpiPens. That’s because a drug’s 340B price is tied to its Medicaid price. House Energy & Commerce Republicans[2] have asked the Department of Health and Human Services Inspector General to investigate whether Mylan’s misclassification of EpiPen as a generic for Medicaid drug rebate purposes has implications for healthcare providers in the 340B drug discount program. Senate Finance Committee Republicans[3] have backed their House colleagues’ request. 

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[4].    Already registered? Click here to login[5]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2016/10/youre-busted-mylan-bilks-medicaid-feds-confirm/

---